StonvexLoading…
StonvexStonvexStonvexCore line items from ADNT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-09-30 | Annual 2024 2024-09-30 | Annual 2023 2023-09-30 | Annual 2022 2022-09-30 |
|---|---|---|---|---|
Revenue | $14.54B | $14.69B | $15.39B | $14.12B |
Operating Income | $-88.00M | $133.00M | $295.00M | $54.00M |
Net Income | $-281.00M | $18.00M | $205.00M | $-120.00M |
EPS (Diluted) | $-3.39 | $0.20 | $2.15 | $-1.27 |
Total Assets | $8.95B | $9.35B | $9.42B | $9.16B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $958.00M | $945.00M | $1.11B | $947.00M |
Free Cash Flow OCF − CapEx | $204.00M | $277.00M | $415.00M | $47.00M |
Shares Outstanding | 79.15M | 84.87M | 93.70M | 94.86M |